These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 16285353

  • 1. Tigecyclin--the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline.
    Felmingham D.
    J Chemother; 2005 Aug; 17 Suppl 1():5-11. PubMed ID: 16285353
    [Abstract] [Full Text] [Related]

  • 2. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
    Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
    [Abstract] [Full Text] [Related]

  • 3. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
    Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
    [Abstract] [Full Text] [Related]

  • 4. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE, Rybak MJ.
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 6. The glycylcyclines: a comparative review with the tetracyclines.
    Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ.
    Drugs; 2004 Jul; 64(1):63-88. PubMed ID: 14723559
    [Abstract] [Full Text] [Related]

  • 7. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
    Projan SJ.
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
    [Abstract] [Full Text] [Related]

  • 8. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR, Kirby JT, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
    [Abstract] [Full Text] [Related]

  • 9. Recent developments in tetracycline antibiotics.
    Sum PE, Sum FW, Projan SJ.
    Curr Pharm Des; 1998 Apr; 4(2):119-32. PubMed ID: 10197036
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines.
    Testa RT, Petersen PJ, Jacobus NV, Sum PE, Lee VJ, Tally FP.
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2270-7. PubMed ID: 8285606
    [Abstract] [Full Text] [Related]

  • 11. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
    Boucher HW, Wennersten CB, Eliopoulos GM.
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2225-9. PubMed ID: 10898710
    [Abstract] [Full Text] [Related]

  • 12. Case studies in current drug development: 'glycylcyclines'.
    Sum PE.
    Curr Opin Chem Biol; 2006 Aug; 10(4):374-9. PubMed ID: 16807065
    [Abstract] [Full Text] [Related]

  • 13. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL, Fung HB, Mehta D, Riska PF.
    Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
    [Abstract] [Full Text] [Related]

  • 14. Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.
    Jones CH, Petersen PJ.
    Drugs Today (Barc); 2005 Oct; 41(10):637-59. PubMed ID: 16389407
    [Abstract] [Full Text] [Related]

  • 15. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
    Zhang YY, Zhou L, Zhu DM, Wu PC, Hu FP, Wu WH, Wang F.
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
    [Abstract] [Full Text] [Related]

  • 16. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to new glycylcyclines in comparison with those to older tetracyclines.
    Kenny GE, Cartwright FD.
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2628-32. PubMed ID: 7872759
    [Abstract] [Full Text] [Related]

  • 17. Tigecycline: a critical analysis.
    Stein GE, Craig WA.
    Clin Infect Dis; 2006 Aug 15; 43(4):518-24. PubMed ID: 16838243
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: an Argentinean multicenter study.
    Casellas JM, Bantar C, Duret F, Argentinean Collaborative Test Group.
    J Chemother; 2007 Oct 15; 19(5):482-7. PubMed ID: 18077902
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group.
    Diagn Microbiol Infect Dis; 2005 Jul 15; 52(3):215-27. PubMed ID: 16105567
    [Abstract] [Full Text] [Related]

  • 20. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options.
    Castanheira M, Mendes RE, Jones RN.
    Clin Infect Dis; 2014 Dec 01; 59 Suppl 6():S367-73. PubMed ID: 25371512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.